Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, With an Open-label Extension

NCT03796962 is registered in ClinicalTrials.gov with Xenon Pharmaceuticals Inc. as lead sponsor.

NCT NCT03796962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03796962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, With an Open-label Extension
Lead sponsor
Xenon Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 30, 2019
Completion date
October 31, 2028
Enrollment
325 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

focal epilepsy